A review of heart failure trials highlighted potential benefits of cardiac contractility devices and selective myosin activators, while oxypurinol showed no overall benefit compared to placebo.
This conference report highlights preliminary findings from early-phase trials of novel heart failure therapies, including contractility devices, myosin activators, and oxypurinol.
This article provides information and a commentary on trials relevant to the pathophysiology, prevention and treatment of heart failure, presented at the Heart Failure Society of America meeting held in Seattle in September 2006. All reports should be considered as preliminary data, as analyses may change in the final publication. Devices designed to improve cardiac contractility may have improved exercise tolerance and quality of life in the FIX-CHF-4 study; however, uncertainties in trial interpretation exist. The results of a study reporting the first administration of the selective myosin activator CK-1827452 to human volunteers, support the initiation of clinical trials in heart failure patients. In OPT-CHF, oxypurinol failed to show benefit compared to placebo for the treatment of heart failure, although a retrospective subgroup analysis suggests that it may be beneficial in patients with elevated serum uric acid levels.
Cleland et al. (Wed,) conducted a review in heart failure. Various heart failure therapies (cardiac contractility devices, CK-1827452, oxypurinol) vs. placebo was evaluated. A review of heart failure trials highlighted potential benefits of cardiac contractility devices and selective myosin activators, while oxypurinol showed no overall benefit compared to placebo.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: